Skip to main content

Table 2 Summary of patient characteristics

From: Clinical characteristics of rheumatoid arthritis patients undergoing cervical spine surgery: an analysis of National Database of Rheumatic Diseases in Japan

Fiscal year 2004 2005 2006 2007 2008 2009 2010
  Cases Total Cases Total Cases Total Cases Total Cases Total Cases Total Cases Total
Age (years) (IQR) 58.5(55.5-72) 63(55–70) 65(62–76) 63(55–70) 60(59–76) 63(56–71) 61(59–63) 64(56–71) 64 64(56–71) 63(58–74) 64(56–72) 65(57–70) 65(57–72)
Gender (female:male) 3:1 3313:681 2:1 3832:818 3:0 4229:923 2:0 4448:1015 1:0 5346:1156 11:2 5895:1284 13:0 5921:1333
Disease dutaion (years) (IQR) 6(4–9) 11(5–19) 15(12–36) 10(5–19) 13(11–30) 10( 5–19) 23.5(15–32) 9(4–19) 24 10(5–19) 16(12–20) 10(5–19) 20(15–40) 10(5–19)
Arthroplastic surgery (IQR) 0(0–0) 0(0–0) 1(0–2) 0(0–0) 1(0–4) 0(0–0) 2(0–3) 0(0–0) 0% 0(0–0) 0(0–3) 0(0–0) 0(0–1) 0(0–0)
Tender joint count (IQR) 9(1–30) 3(1–6) 15(13–16) 3(1–6) 1(0–4) 2(1–6) 19(4–34) 2(0–5) 4 2(0–5) 3(1–9) 2(0–4) 2(1–4) 1(0–3)
Swollen joint count (IQR) 2(0–10) 2(0–5) 0(0–4) 2(0–5) 0(0–2) 1(0–4) 3(3–3) 1(0–3) 3 1(0–4) 2(0–6) 1(0–3) 2(0–5) 1(0–3)
MHAQ (IQR) 1.4(0.35-1.48) 0.5(0–1) 2.3(1.3-2.9) 0.4(0–1) 1.5(0.88-2) 0.4(0–1) 1.55(1–2.1) 0.4(0–1) 1.25 0.38(0–1) 1(0.69-1.44) 0.25(0–0.9) 1(0.26-1.94) 0.25(0–0.9)
CRP (mg/dl) (IQR) 3.4(0.9-4.2) 0.59(0.18-1.7) 2.7(1.75-3.35) 0.55(0.18-1.57) 0.47(0.05-0.71) 0.47(0.18-1.4) 1.26(1.02-1.5) 0.41(0.17-1.22) 1.95 0.31(0.13-1.03) 1.04(0.18-2.78) 0.28(0.11-0.9) 2.0(0.14-3.5) 0.26(0.1-0.76)
ESR (mm/h) (IQR) 38.5(14–66) 37(20–60) 43(17–77) 35(19–56) 23(9–46) 33(18–55) 74.5(46–103) 31(16–51) 51 29(15–49) 37.5(29–71.3) 28(14–47) 55.5(5.5-84.8) 25(13–45)
DAS28-CRP (IQR) 4.15(3.15-6.11) 3.34(2.45-4.25) 4.71(4.67-5.38) 3.35(2.43-4.24) 2.98(1.13-3.61) 3.14(2.29-4.06) 4.93(3.46-6.39) 2.99(2.12-3.89) 4.19 2.85(2.04-3.75) 3.32(2.58-4.46) 2.72(1.94-3.6) 3.39(2.3-4.78) 2.55(1.83-3.46)
Stage1 (%) 0 14.5 0 15 0 15.9 0 17.7 0 16.6 8.3 18 7.7 19.6
Stage2 (%) 100 25 33.3 25.2 0 25 0 25.7 0 25.6 0 27.2 0 26.5
Stage3 (%) 0 21 33.3 20.3 0 19.9 50 20.4 0 20.7 25 19.3 15.4 19.6
Stage4 (%) 0 39.5 33.3 39.5 100 39.2 50 36.2 100 37.1 66.7 35.5 76.9 34.3
Class1 (%) 0 25 0 26.2 0 26.2 0 26.9 0 25.3 25 26 0 28.2
Class2 (%) 75 52.7 0 53.4 33.3 53.3 0 52.9 0 52 50 53.9 61.5 52.6
Class3 (%) 25 19.1 66.7 17.4 66.7 17.4 100 17.5 0 19.3 25 16.8 38.5 16.4
Class4 (%) 0 3.2 33.3 3 0 3.1 0 2.7 100 3.4 0 3.3 0 2.8
PtPainVAS (IQR) 5.5(2.3-7.0) 3.3(1.6-5.5) 6.1(4–7) 3.1(1.5-5.3) 5.5(1.6-6.8) 3(1.4-5.2) 5.5(2.5-8.5) 3(1.3-5.1) 4.3 2.6(1.1-5) 3.4(1.4-8.3) 2.6(1.1-5) 2.25(0.98-4.95) 2.4(1–4.8)
PtGVAS (IQR) 5.7(3–8.4) 3.5(1.7-5.5) 6.8(2.3-8.1) 3.4(1.6-5.3) 5.9(0.2-7.8) 3.2(1.5-5.2) 5.5(2.5-8.5) 3(1.4-5.1) 5.3 2.8(1.2-5) 4.7(0.85-7.75) 2.7(1.2-5) 3.1(1.85-5.9) 1.6(0.7-2.9)
DrGVAS (IQR) 7(3.4-8.3) 2.5(1.3-4.1) 5.2(3.1-7) 2.4(1.1-4) 0.7(0.5-3.4) 2(1–3.5) 6.15(3.3-9) 1.8(0.9-3.1) 2.6 1.6(0.6-3) 3.8(0.8-4.8) 1.8(0.8-3) 2.5(1.05-4.4) 0.25(0–0.88)
Use of MTX (%) 33 48 0 53 100 53.9 50 47.3 0 51.1 53.8 64.3 0 58.2
Use of corticosteroid (%) 100 63 100 62 100 64 100 61 100 59.1 100 53 84.6 53.4
Use of biologics (%) 0 2.1 0 4.3 0 9 0 11.7 0 13.6 38.5 20 0 18.6
  1. VAS: visual analog scale, MHAQ: Modified Health Assessment Questionnaire, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, DAS28: Disease Activity Score of 28 Joints, MTX: Methotrexate.
  2. A comparison of the cases and total number of patients enrolled in the same fiscal year. The data are presented as the medians (IQR).